MetaVia’s DA-1726 obesity candidate shows efficacy in Part 2 of Phase 1 study

MetaVia (MTVA) reported additional top-line results from the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor, further demonstrating its potential as a best-in-class obesity drug. In the 28-day, 36-subject MAD portion of the study, a clear dose-responsive trend in body weight reduction was observed across the 8 mg to 32 mg range, indicating potentially greater efficacy at higher doses and longer duration of use. Additionally, body mass index, which shows body weight adjusted for height, showed a difference between the treatment group and the placebo group, which was even more pronounced, further supporting the dose-dependent effect of the drug on weight-related outcomes. DA-1726 did not show any clinically significant increases in heart rate or QTcF changes up to 32 mg at 4 weeks of administration. DA-1726’s 3:1 balanced activation of GLP-1 and glucagon receptors offers a promising alternative to current GLP-1 agonists, addressing the significant tolerability challenges that lead to 20-30% discontinuation within the first month and up to 70% within a year. A Phase 1 Part 3 study is planned to evaluate DA-1726 patients who discontinued Wegovy early, aiming to demonstrate improved tolerability, safety, and weight loss outcomes. DA-1726 demonstrated safety and tolerability, with positive clinical activity. There were no treatment-related discontinuations or SAEs. Early satiety was observed in 83% of subjects receiving the 32 mg dose, suggesting the potential for greater weight loss with longer treatment duration.